Response of neovascular central serous chorioretinopathy to an extended upload of anti-vegf agents
International Journal of Development Research
Response of neovascular central serous chorioretinopathy to an extended upload of anti-vegf agents
Received 11th March, 2020; Received in revised form 22nd April, 2020; Accepted 27th May, 2020; Published online 25th June, 2020
Copyright © 2020, Dan Călugăru and Mihai Călugăru. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The authors are commenting on the study entitled “Response of neovascular central serous chorioretinopathy to an extended upload of anti-VEGF agents” published by Schworm et al. in Graefe Arch Clin Exp Ophthalmol 2020;258(5):1013-1021, which retrospectively evaluated the anatomical and functional outcomes of an extended 6-month intravitreal anti-vascular endothelial growth factor upload in choroidal neovascularization secondary to chronic central serous chorioretinopathy. The database analysis included 21 eyes of 21 patients. The authors concluded that a strict injection regimen for neovascular central serous chorioretinopathy can lead to a favorable anatomical and functional treatment response attributable not only to the substantial effect of the anti-vascular endothelial growth factor therapy but also to a modulation of choroidal perfusion. We agree with these findings only after the statistical analyses will encompass all the missing baseline potential predictive factors referred to by us in addition to the baseline characteristics already evaluated in this study, serving to highlight the key metrics of the response of neovascular central serous chorioretinopathy to an extended upload of anti-vascular endothelial growth factor agents.
